417 related articles for article (PubMed ID: 26858599)
1. The Ubiquitin-Proteasome System: Potential Therapeutic Targets for Alzheimer's Disease and Spinal Cord Injury.
Gong B; Radulovic M; Figueiredo-Pereira ME; Cardozo C
Front Mol Neurosci; 2016; 9():4. PubMed ID: 26858599
[TBL] [Abstract][Full Text] [Related]
2. Relationship between amyloid-beta and the ubiquitin-proteasome system in Alzheimer's disease.
Hong L; Huang HC; Jiang ZF
Neurol Res; 2014 Mar; 36(3):276-82. PubMed ID: 24512022
[TBL] [Abstract][Full Text] [Related]
3. Exploring the Promise of Targeting Ubiquitin-Proteasome System to Combat Alzheimer's Disease.
Al Mamun A; Uddin MS; Kabir MT; Khanum S; Sarwar MS; Mathew B; Rauf A; Ahmed M; Ashraf GM
Neurotox Res; 2020 Jun; 38(1):8-17. PubMed ID: 32157628
[TBL] [Abstract][Full Text] [Related]
4. Frameshift proteins in Alzheimer's disease and in other conformational disorders: time for the ubiquitin-proteasome system.
van Leeuwen FW; Hol EM; Fischer DF
J Alzheimers Dis; 2006; 9(3 Suppl):319-25. PubMed ID: 16914870
[TBL] [Abstract][Full Text] [Related]
5. Molecular Insight into the Crosstalk of UPS Components and Alzheimer's Disease.
Al Mamun A; Rahman MM; Zaman S; Munira MS; Uddin MS; Rauf A; Banu N; Ashraf GM
Curr Protein Pept Sci; 2020; 21(12):1193-1201. PubMed ID: 32964822
[TBL] [Abstract][Full Text] [Related]
6. Role of the ubiquitin-proteasome system in brain ischemia: friend or foe?
Caldeira MV; Salazar IL; Curcio M; Canzoniero LM; Duarte CB
Prog Neurobiol; 2014 Jan; 112():50-69. PubMed ID: 24157661
[TBL] [Abstract][Full Text] [Related]
7. Paradoxical effects of mutant ubiquitin on Aβ plaque formation in an Alzheimer mouse model.
Verheijen BM; Stevens JAA; Gentier RJG; van 't Hekke CD; van den Hove DLA; Hermes DJHP; Steinbusch HWM; Ruijter JM; Grimm MOW; Haupenthal VJ; Annaert W; Hartmann T; van Leeuwen FW
Neurobiol Aging; 2018 Dec; 72():62-71. PubMed ID: 30216939
[TBL] [Abstract][Full Text] [Related]
8. Targeting Ubiquitin-Proteasome Pathway by Natural Products: Novel Therapeutic Strategy for Treatment of Neurodegenerative Diseases.
Momtaz S; Memariani Z; El-Senduny FF; Sanadgol N; Golab F; Katebi M; Abdolghaffari AH; Farzaei MH; Abdollahi M
Front Physiol; 2020; 11():361. PubMed ID: 32411012
[TBL] [Abstract][Full Text] [Related]
9. P2X7 receptor inhibition ameliorates ubiquitin-proteasome system dysfunction associated with Alzheimer's disease.
Bianchi C; Alvarez-Castelao B; Sebastián-Serrano Á; Di Lauro C; Soria-Tobar L; Nicke A; Engel T; Díaz-Hernández M
Alzheimers Res Ther; 2023 Jun; 15(1):105. PubMed ID: 37287063
[TBL] [Abstract][Full Text] [Related]
10. The role of ubiquitin C-terminal hydrolase L1 in neurodegenerative disorders.
Gong B; Leznik E
Drug News Perspect; 2007; 20(6):365-70. PubMed ID: 17925890
[TBL] [Abstract][Full Text] [Related]
11. Increased Cerebrospinal Fluid Levels of Ubiquitin Carboxyl-Terminal Hydrolase L1 in Patients with Alzheimer's Disease.
Öhrfelt A; Johansson P; Wallin A; Andreasson U; Zetterberg H; Blennow K; Svensson J
Dement Geriatr Cogn Dis Extra; 2016; 6(2):283-94. PubMed ID: 27504117
[TBL] [Abstract][Full Text] [Related]
12. Genetic association between Ubiquitin Carboxy-terminal Hydrolase-L1 gene S18Y polymorphism and sporadic Alzheimer's disease in a Chinese Han population.
Xue S; Jia J
Brain Res; 2006 May; 1087(1):28-32. PubMed ID: 16626667
[TBL] [Abstract][Full Text] [Related]
13. Exploration of Aberrant E3 Ligases Implicated in Alzheimer's Disease and Development of Chemical Tools to Modulate Their Function.
Potjewyd FM; Axtman AD
Front Cell Neurosci; 2021; 15():768655. PubMed ID: 34867205
[TBL] [Abstract][Full Text] [Related]
14. Ubiquitin hydrolase Uch-L1 rescues beta-amyloid-induced decreases in synaptic function and contextual memory.
Gong B; Cao Z; Zheng P; Vitolo OV; Liu S; Staniszewski A; Moolman D; Zhang H; Shelanski M; Arancio O
Cell; 2006 Aug; 126(4):775-88. PubMed ID: 16923396
[TBL] [Abstract][Full Text] [Related]
15. Expression in the mammalian retina of parkin and UCH-L1, two components of the ubiquitin-proteasome system.
Esteve-Rudd J; Campello L; Herrero MT; Cuenca N; Martín-Nieto J
Brain Res; 2010 Sep; 1352():70-82. PubMed ID: 20638372
[TBL] [Abstract][Full Text] [Related]
16. The Ubiquitin System in Alzheimer's Disease.
Harris LD; Jasem S; Licchesi JDF
Adv Exp Med Biol; 2020; 1233():195-221. PubMed ID: 32274758
[TBL] [Abstract][Full Text] [Related]
17. Role of the ubiquitin proteasome system in Alzheimer's disease.
Upadhya SC; Hegde AN
BMC Biochem; 2007 Nov; 8 Suppl 1(Suppl 1):S12. PubMed ID: 18047736
[TBL] [Abstract][Full Text] [Related]
18. The Decrease of Uch-L1 Activity Is a Common Mechanism Responsible for Aβ 42 Accumulation in Alzheimer's and Vascular Disease.
Guglielmotto M; Monteleone D; Vasciaveo V; Repetto IE; Manassero G; Tabaton M; Tamagno E
Front Aging Neurosci; 2017; 9():320. PubMed ID: 29033830
[TBL] [Abstract][Full Text] [Related]
19. Localization of mutant ubiquitin in the brain of a transgenic mouse line with proteasomal inhibition and its validation at specific sites in Alzheimer's disease.
Gentier RJ; Verheijen BM; Zamboni M; Stroeken MM; Hermes DJ; Küsters B; Steinbusch HW; Hopkins DA; Van Leeuwen FW
Front Neuroanat; 2015; 9():26. PubMed ID: 25852488
[TBL] [Abstract][Full Text] [Related]
20. Mutant ubiquitin decreases amyloid β plaque formation in a transgenic mouse model of Alzheimer's disease.
van Tijn P; Dennissen FJ; Gentier RJ; Hobo B; Hermes D; Steinbusch HW; Van Leeuwen FW; Fischer DF
Neurochem Int; 2012 Oct; 61(5):739-48. PubMed ID: 22797007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
